New drug combo targets hard-to-treat brain tumors in early trial
NCT ID NCT05484622
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 26 times
Summary
This early-phase study tests whether combining vorasidenib (a targeted therapy) with pembrolizumab (an immunotherapy) is safe and can boost the immune system's attack on recurrent IDH-1 mutant gliomas, a type of brain tumor. About 60 adults with grade 2 or 3 astrocytoma or oligodendroglioma will receive the drugs before and after surgery. The main goals are to check for side effects and measure immune cell activity in the tumor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OLIGODENDROGLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Dana-Farber Cancer Institute (Site: 840139)
Boston, Massachusetts, 02215, United States
-
Duke University (Site: 840110)
Durham, North Carolina, 27705, United States
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
-
MD Anderson Cancer Center (Site: 840102)
Houston, Texas, 77030, United States
-
Massachusetts General Hospital (Site: 840104)
Boston, Massachusetts, 02114, United States
-
Mayo Clinic Florida
Cleveland, Ohio, 44195, United States
-
Memorial Sloan Kettering Cancer Center (Site: 840117)
New York, New York, 10017, United States
-
Northwestern University (Site: 840123)
Chicago, Illinois, 60045, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35249, United States
-
University of California, Los Angeles (Site: 840113)
Los Angeles, California, 90095, United States
-
University of California, San Francisco (Site: 840149)
San Francisco, California, 94013, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
-
University of Miami (Site: 840129)
Miami, Florida, 33136, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of Pennsylvania Health System
Philadelphia, Pennsylvania, 19104, United States
-
University of Utah, Huntsman Cancer Center
Salt Lake City, Utah, 84112, United States
Conditions
Explore the condition pages connected to this study.